alexa Tumor Control By Genetically Engineered CD8+ And CD4+ T Cells | 22741
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th World Congress on Cancer Science & Therapy

Immanuel Luescher
Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.035
Abstract
This lecture will focus on tumor control by genetically engineered CD8+ and CD4+ T cells. A critical overview of different strategies of cancer gene therapies including adoptive transfer of autologous of CD8+ and CD4+ T cells transduced with genes coding for affinity optimized T cell receptors (TCR) or chimeric antigen receptors (CAR) will be presented. Detailed mechanistic studies will be discussed on how adoptive transfer of tumor-specific CD8+ T cells engineered to express high FasL and IFNγ expression and CAR engineered CD4+ T cells, respectively, mediate complete and permanent tumor eradication. In both cases the transferred T cells reprogrammed the tumor environment from a suppressive one to one supportive for the induction and amplification of endogenous tumor-specific T cell immunity and capable to destroy established tumors. Future perspectives will be discussed, how tumor microenvironments can be manipulated to achieve tumor control by altering balance between immunity and suppression.
Biography
Immanuel Luescher and is the head of the Molecular Immunology unit and author of over 133 peer reviewed articles. He is reviewing for different journals and committees responsible for grant allocations and recruitments. In over 25 years of research different aspects of activation and inactivation of cytotoxic CD8+ T and CD4+ T cells were investigated. More recently research is mainly focused on tumor control and reprograming tumor micro-environments. He is president of TCMetrix a Swiss based Ltd, providing high quality soluble MHC class I and class II ? peptide complexes in various formats.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7